Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Sports Med ; 40(12): 803-809, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31476781

RESUMO

The use of injections to treat structural muscle injuries is controversially discussed. In our controlled in vitro study, we investigated the biological impact of Actovegin and Traumeel alone and in combination on primary human skeletal muscle cells. Cells were characterized by immunofluorescence staining for myogenic factor 5 (Myf5) and MyoD, and cultured with or without Actovegin and / or Traumeel. The effects of these agents were assayed by cell viability and gene expression of the specific markers MyoD, Myf5, neural adhesion molecule (NCAM), and CD31. Myotube formation was determined by myosin staining. Neither Actovegin nor Traumeel showed toxic effects or influenced cell viability significantly. High volumes of Actovegin down-regulated gene expression of NCAM after 3 days but had no effect on MyoD, Myf5, and CD31 gene expression. High volumes of Traumeel inhibited MyoD gene expression after 3 days, whereas after 7 days MyoD expression was significantly up-regulated. The combination of both agents did not significantly influence cell viability or gene expression. This is the first study demonstrating that Actovegin and Traumeel potentially modulate human skeletal muscle cells. The relevance of these in vitro findings has to be highlighted in further in vivo studies.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Heme/análogos & derivados , Minerais/farmacologia , Fibras Musculares Esqueléticas/fisiologia , Extratos Vegetais/farmacologia , Adulto , Idoso , Antígeno CD56/efeitos dos fármacos , Antígeno CD56/genética , Sobrevivência Celular , Células Cultivadas , Relação Dose-Resposta a Droga , Regulação para Baixo , Heme/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Proteína MyoD/efeitos dos fármacos , Proteína MyoD/genética , Fator Regulador Miogênico 5/efeitos dos fármacos , Fator Regulador Miogênico 5/genética , Molécula-1 de Adesão Celular Endotelial a Plaquetas/efeitos dos fármacos , Molécula-1 de Adesão Celular Endotelial a Plaquetas/genética
2.
Oral Dis ; 19(7): 702-11, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23294197

RESUMO

OBJECTIVES: Chronic intermittent hypoxia (CIH) is a frequent feature of OSAHS. The present study was designed to evaluate the effects of genistein and estrogen on genioglossus contractile and regeneration properties in CIH rats and investigate the involvement of HIF-1α. METHODS: Ovariectomized female rats were exposed to CIH for 5 weeks. Genistein and estrogen were administered by intraperitoneal injection. The genioglossus myoblasts of rat were also isolated and cultured in vitro, and the HIF-1α shRNA lentivirus was used. RESULTS: Muscle fatigue resistance and myogenic regeneration were significantly decreased after CIH but were partially reversed by estrogen and genistein treatment. The effect of estrogen was more powerful than that of genistein. Compared with control group, RT-PCR and western blotting showed higher levels of HIF-1α mRNA and protein in the CIH group, but estrogen and genistein treatment reduced the levels of HIF-1α mRNA and protein in rats exposed to CIH. In genioglossus myoblasts, the expression of HIF-1α was up-regulated under hypoxia rather than normoxia and decreased over time under both hypoxia and normoxia during myogenic differentiation. HIF-1α knockdown relieved myogenesis inhibition under hypoxia. CONCLUSION: We concluded that genistein and estrogen may inhibit the overexpression of HIF-1α induced by CIH and improve the endurance and regeneration of the genioglossus muscle.


Assuntos
Estrogênios/farmacologia , Genisteína/farmacologia , Subunidade alfa do Fator 1 Induzível por Hipóxia/efeitos dos fármacos , Músculos Faríngeos/efeitos dos fármacos , Fitoestrógenos/farmacologia , Apneia Obstrutiva do Sono/fisiopatologia , Animais , Células Cultivadas , Modelos Animais de Doenças , Estrogênios/administração & dosagem , Feminino , Técnicas de Silenciamento de Genes , Inativação Gênica , Genisteína/administração & dosagem , Subunidade alfa do Fator 1 Induzível por Hipóxia/análise , Injeções Intraperitoneais , Lentivirus/genética , Contração Muscular/efeitos dos fármacos , Desenvolvimento Muscular/efeitos dos fármacos , Fadiga Muscular/efeitos dos fármacos , Proteína MyoD/efeitos dos fármacos , Mioblastos Esqueléticos/efeitos dos fármacos , Fator Regulador Miogênico 5/efeitos dos fármacos , Cadeias Pesadas de Miosina/efeitos dos fármacos , Ovariectomia , Fitoestrógenos/administração & dosagem , RNA Interferente Pequeno/genética , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Regeneração/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...